Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

British journal of cancer - 11 Oct 2011

Horiike A, Kudo K, Miyauchi E, Ohyanagi F, Kasahara K, Horai T, Nishio M

Abstract excerpt

BACKGROUND: Currently, no effective treatments exist for non-small cell lung cancer (NSCLC) after failure of gefitinib therapy. Pre-clinical studies have demonstrated that gefitinib-resistant NSCLC cells are more sensitive to irinotecan than parental cells, and that combined administration of irinotecan and gefitinib has a synergistic additive effect. We conducted a phase I study to evaluate the combination of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Gefitinib

Share to Irinotecan

Share to Maximum Tolerated Dose

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 21915126
DOI: 10.1038/bjc.2011.375
PMCID: PMC3208500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.PMID 21915126Read ↗

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.Semantic proximity Read ↗

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.Semantic proximity Read ↗

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.Semantic proximity Read ↗

Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).Semantic proximity Read ↗

Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.Semantic proximity Read ↗

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.Semantic proximity Read ↗

[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].Semantic proximity Read ↗

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Geftinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.